AMG: Analysis & Opinions

  1. Amgen Chased By The Bubble

    May 08, 2013
    Amgen really needs the pipeline to come through to support this valuation.
  2. Amgen Provides Long-Term Update - Analyst Blog

    February 13, 2013
    Amgen (AMGN) recently provided an update on its long-term strategy. The company said that it intends to focus on the ...
  3. UCB, Amgen Discontinue Study - Analyst Blog

    February 12, 2013
    UCB (UCBJF) and Amgen Inc. (AMGN) recently announced their decision to discontinue a phase III program being ...
  4. Actavis Provides 2013 Guidance - Analyst Blog

    January 31, 2013
    Actavis, Inc. (ACT), formerly known as Watson Pharmaceuticals, Inc., recently provided an update on its 2012 ...
  5. Affiliated Managers Beats on EPS - Analyst Blog

    January 30, 2013
    Affiliated Managers Group, Inc.'s (AMG) fourth quarter 2012 economic net income (ENI) came in at $2.55 per share, ...
  6. T. Rowe Price Missed Marginally - Analyst Blog

    January 29, 2013
    T. Rowe Price Group, Inc. (TROW) reported its fourth-quarter 2012 net income of 88 cents per share, a penny below ...
  7. Safest Way to Play Biotech - Cook`s Kitchen

    January 25, 2013
    Investing in biotechnology can be exciting, profitable, and loaded with land mines. For every company that hits the ...
  8. Amgen Misses on EPS, Guides Above - Analyst Blog

    January 24, 2013
    Amgen (AMGN) reported fourth quarter 2012 earnings of $1.39 per share, 4 cents below the Zacks Consensus Estimate. ...
  9. Earnings Preview: Amgen - Analyst Blog

    January 22, 2013
    Amgen (AMGN) is scheduled to report its fourth quarter 2012 results on Jan 23, 2013 after the closing bell. Last ...
  10. Management Expands at AstraZeneca - Analyst Blog

    January 17, 2013
    AstraZeneca (AZN) recently announced that the company has created seven positions in the senior executive team. At ...
  11. Canadian Approval for BMY's Drug - Analyst Blog

    January 16, 2013
    Good news flowed in at Bristol-Myers Squibb (BMY) from Canada when Health Canada, the federal department responsible ...
  12. Biogen Submits Hemophilia B BLA - Analyst Blog

    January 08, 2013
    Biogen Idec (BIIB) recently submitted a Biologics License Application (BLA) seeking US Food and Drug Administration ...
  13. BioMimetic's Pipeline Progresses - Analyst Blog

    January 07, 2013
    Biotechnology company, BioMimetic Therapeutics, Inc. (BMTI) recently announced that it has started enrolling ...
  14. Berkshire Hathaway and More Big Movers in Financial on ...

    January 02, 2013
    The market is on the rise this morning. The Nasdaq has climbed 2.3%; the S&P 500 has risen 1.8%; and the Dow is up ...
  15. Positive Data on Actelion Candidate - Analyst Blog

    December 19, 2012
    Actelion (ALIOF) recently announced positive results from a phase II study on its S1P1 modulator, ponesimod. ...
  16. Bear of the Day: Align Technology (ALGN) - Bear of the Day

    December 12, 2012
    Align Technology's (ALGN) third quarter 2012 results were dismal with the company reporting revenues and adjusted ...
  17. Bull of the Day: Amgen (AMGN) - Bull of the Day

    December 12, 2012
    Amgen Inc's (AMGN) third quarter EPS of $1.66 per share was 23 cents above the Zacks Consensus Estimate and 19.4% ...
  18. Abbott's Humira's Label Expanded - Analyst Blog

    November 28, 2012
    Abbott Labs (ABT) recently received approval for yet another indication of Humira (adalimumab). The European ...
  19. Goldman Sachs Among Financial's Biggest Movers on ...

    November 19, 2012
    The Nasdaq has moved up 1.7%, the S&P 500 is trading up 1.5% and the Dow has increased 1.3%, marking a bad morning ...
  20. Biotech ETFs: A Fiscal Cliff Safe Haven? - ETF News And ...

    November 16, 2012
    With the election over, many investors assumed that one of the key risk events for U.S. markets was past us. ...
Marketplace
Trading Center